ADPS™
BRAF Mutation Test Kit v1
Accurate diagnosis, specific prescription
Accurate diagnosis, specific prescription
BRAF is a serine/threonine kinase that functions in the Ras-Raf-MEK-MAPK pathway and has been implicated in cancer development. The most common BRAF mutation, BRAF V600, results in the permanent activation of the BRAF protein without growth factors, leading to excessive cell proliferation and resistance to apoptosis.
BRAF mutations are commonly found in thyroid cancer and cutaneous melanoma. They are reported to occur at a frequency of approximately 35% in melanoma and 65% in thyroid cancer. Treatments targeting BRAF have shown clinical benefit in most patients with BRAF V600 mutations.
The ADPS™ BRAF Mutation Test Kit v1 detects four mutations in BRAF, including two V600E and two V600D mutations, with a detection sensitivity of 0.01%. It is designed to allow testing of both tissue and plasma samples with a single kit.
In Europe, medical professionals can diagnose patients based on the analysis results. In other regions, it is for research use only (RUO) and cannot be used in diagnostic procedures.
| Catalog No. | (IVD) D8004APA (RUO) R8004APA |
|---|---|
| Detection target | 4 mutations in BRAF V600 codon (two V600E mutations and two V600D mutations) |
| Assay type | qPCR |
| Sample type | DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy |
| Master Mixture (MMX) |
1MMXs |
| Internal Control | BRAF intron 1 |
| Detection Sensitivity | 0.01% |
| Detection Specificity | ≥ 99.3% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 18 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | AB 7500 Fast, CFX96, QuantStudio 5 |
ADPS™ Oncogene Mutation Test